US Patent Issued to Genentech on May 6 for "Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin" (California Inventors)

ALEXANDRIA, Va., June 10 -- United States Patent no. 12,291,575, issued on May 6, was assigned to Genentech Inc. (South San Francisco, Calif.).

"Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin" was invented by Carol Elaine O'Hear (South San Francisco, Calif.), Yasuhiro Oki (South San Francisco, Calif.) and Iris Tranthuyngan To (South San Francisco, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to the treatment of subjects having a CD20-positive cell proliferative disorder. More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder by administering a com...